REGULATORY

Chuikyo’s HTA Panel Issues Interim Report, Appraisal Results to Be Used to Re-Price Selected Listed Drugs

August 27, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council’s (Chuikyo) subcommittee on cost-effective assessments compiled an interim report on August 26 towards the trial introduction of healthcare technology assessments (HTAs) scheduled for the next fiscal year. The report, which was approved at Chuikyo’s…

To read the full story

Reflect Industry Opinions in Pilot Introduction of Cost-Effective Assessments: JPMA
October 27, 2015

REGULATORY

Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
May 29, 2026
LDP HQ Finalizes Recommendations ahead of Growth Strategy
May 29, 2026
Japan Eyes Broader Healthcare Measures Addressing Sex-Based Health Issues
May 28, 2026
MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…